Where is Ipsen headquartered?

Ipsen is recorded with headquarters in Paris, FR in NovaPharmaNews public regulatory and sponsor datasets.

Is Ipsen publicly traded?

Ipsen is represented in our database primarily through regulatory marketing authorisation or trial sponsor records; it may not have a US listed ticker in SEC EDGAR.

What drugs are associated with Ipsen?

We link 5 drug profile(s) where Ipsen appears as originator or marketer in FDA or regional approval metadata.

What clinical trials is Ipsen sponsoring?

Ipsen is linked to 27 pipeline program(s) sourced from ClinicalTrials.gov and EU CTIS where sponsor names match.

What patents list Ipsen as applicant?

No US patent records are currently linked to this company profile.

What pipeline phases does Ipsen have in our database?

Phase distribution from linked programs: phase 2: 12, phase 3: 10, phase 1: 3, approved: 2.

How many US-approved drugs are linked to Ipsen?

4 linked drug profile(s) include US approval status in openFDA-derived metadata.

Does Ipsen hold EU marketing authorisations in our data?

4 linked drug(s) include EMA EPAR approval metadata.

Where does NovaPharmaNews source data on Ipsen?

Profiles combine SEC EDGAR (US issuers), FDA openFDA, EMA medicines data, ClinicalTrials.gov, EU CTIS, USPTO PatentsView, and regional PBS/PMDA/NMPA feeds. See /about/data-sources.

Is Ipsen data investment advice?

No. This profile is compiled from public regulatory records for professional reference only, not investment or medical advice.

Ipsen Pharmaceuticals Company Profile | Pipeline, Drugs, Clinical…

Name: Ipsen intelligence dataset
Creator: NovaPharmaNews
License: https://www.sec.gov/edgar.shtml

Company details

Status: Public
HQ: 70, Rue Balard, Paris, Île-de-France 75015, FR
Employees: 6,584
Programs: 27
Drugs: 36
Patents: 0

Official website ↗ All projects Drug pipeline News & analysis

Quick answer

Ipsen is a pharma organization headquartered in Paris, FR. Primary therapeutic focus areas include Metastatic Pancreatic Adenocarcinoma, Primary Biliary Cholangitis, Episodic Migraine, Alagille Syndrome, Not applicable. NovaPharmaNews links 27 clinical program(s), 5 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (12), phase 3 (10), phase 1 (3).

Company snapshot

We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the worl

8 approved product(s) across US/EU regulatory metadata.
27 active pipeline program(s) linked via ClinicalTrials.gov.
27 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Ipsen. Not investment advice.

Top assets

View drugs (36) View projects (27)

Lead pipeline drugs

abobotulinumtoxina
approved
abraxane
Marketed / approved
botulinum toxin type a
Marketed / approved
cabozantinib
approved

Active clinical programs

A4250-015 Alagille Syndrome
Phase 3
Botulinum toxin type A Low Back Pain
Phase 3
CLIN-10200-458 Treatment of moderate to severe glabellar lines
Phase 3
CLIN-52120-463 Chronic migraine
Phase 3

Momentum

Proprietary activity score for Ipsen.

1 active signal

20 /100 +0 vs 30 days ago

Signal breakdown

Clinical trials 4 30d
Nova articles 0 30d
Patents filed 0 30d
FDA actions 0 30d
SEC filings 0 30d
Conference presentations 0 90d
Pipeline advances 0 30d

Competitor landscape

Therapeutic-area overlap peers from registry and pipeline signals.

Peer + 0 momentum

Mirum Pharmaceuticals International

TA overlap score 25

Recent activity

Latest pipeline, patent, and corporate events for Ipsen.

Jun 8, 2026 Clinical update
CLIN-10200-458 — Phase 3
Jun 8, 2026 Clinical update
CLIN-52120-464 — Phase 3
Jun 8, 2026 Clinical update
CLIN-52120-463 — Phase 3
Jun 8, 2026 Clinical update
CLIN-52120-452 — Approved
Jun 8, 2026 Clinical update
CLIN-01194-450 — Phase 2

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

What is Ipsen?

Ipsen is a pharma organization headquartered in Paris, FR. Primary therapeutic focus areas include Metastatic Pancreatic Adenocarcinoma, Primary Biliary Cholangitis, Episodic Migraine, Alagille Syndrome, Not applicable. NovaPharmaNews links 27 clinical program(s), 5 drug profile(
Is Ipsen publicly traded?

Ipsen appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.
What drugs does Ipsen develop or market?

We link 36 drug profile(s) where Ipsen is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/ipsen-pharma#company-drugs.
What are the latest developments for Ipsen?

In the last 12 months our linked public records show 27 trial program update(s) and 0 US patent grant(s) tied to this profile.
What therapeutic areas does Ipsen focus on?

Ipsen focuses on Metastatic Pancreatic Adenocarcinoma, Primary Biliary Cholangitis, Episodic Migraine based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others

Oncology